JP2021511352A - 急性骨髄性白血病の併用処置 - Google Patents

急性骨髄性白血病の併用処置 Download PDF

Info

Publication number
JP2021511352A
JP2021511352A JP2020540571A JP2020540571A JP2021511352A JP 2021511352 A JP2021511352 A JP 2021511352A JP 2020540571 A JP2020540571 A JP 2020540571A JP 2020540571 A JP2020540571 A JP 2020540571A JP 2021511352 A JP2021511352 A JP 2021511352A
Authority
JP
Japan
Prior art keywords
hydrate
acceptable salt
pharmaceutically acceptable
mmol
bet inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020540571A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511352A5 (https=
JPWO2019145410A5 (https=
Inventor
ウルリケ トンチュ−グルント
ウルリケ トンチュ−グルント
アンケ バウム
アンケ バウム
ドロテア イングリッド ルドルフ
ドロテア イングリッド ルドルフ
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング, ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2021511352A publication Critical patent/JP2021511352A/ja
Publication of JP2021511352A5 publication Critical patent/JP2021511352A5/ja
Publication of JPWO2019145410A5 publication Critical patent/JPWO2019145410A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020540571A 2018-01-25 2019-01-24 急性骨髄性白血病の併用処置 Pending JP2021511352A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18153471 2018-01-25
EP18153471.0 2018-01-25
PCT/EP2019/051733 WO2019145410A1 (en) 2018-01-25 2019-01-24 Combination treatment of acute myeloid leukemia

Publications (3)

Publication Number Publication Date
JP2021511352A true JP2021511352A (ja) 2021-05-06
JP2021511352A5 JP2021511352A5 (https=) 2022-02-01
JPWO2019145410A5 JPWO2019145410A5 (https=) 2022-02-01

Family

ID=61198661

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020540571A Pending JP2021511352A (ja) 2018-01-25 2019-01-24 急性骨髄性白血病の併用処置

Country Status (5)

Country Link
US (1) US20210038602A1 (https=)
EP (1) EP3743067A1 (https=)
JP (1) JP2021511352A (https=)
CN (1) CN111629725A (https=)
WO (1) WO2019145410A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220356525A1 (en) * 2019-10-16 2022-11-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether patients suffering from acute myeloid leukemia will achieve a response to an myc-targeting therapy
WO2022184664A1 (en) 2021-03-02 2022-09-09 Boehringer Ingelheim International Gmbh Anticancer combination therapy

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015531365A (ja) * 2012-09-28 2015-11-02 オンコエシックス エスエー チエノトリアゾロジアゼピン化合物を含む医薬製剤
JP2015537021A (ja) * 2012-11-16 2015-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング トリアゾロピラジン
JP2016530259A (ja) * 2013-08-14 2016-09-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジノン
JP2016540742A (ja) * 2013-11-07 2016-12-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｒｄ４阻害薬としてのトリアゾロピラジン誘導体
JP2017517565A (ja) * 2014-05-09 2017-06-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンゾイミダゾール誘導体
JP2017529358A (ja) * 2014-09-19 2017-10-05 ジェネンテック， インコーポレイテッド がんの処置のためのｃｂｐ／ｅｐ３００阻害剤およびｂｅｔ阻害剤の使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0318145A (pt) 2003-02-26 2006-02-21 Boehringer Ingelheim Pharma dihidropteridinonas, processos para a sua preparação e sua aplicação como medicamento
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
WO2013033270A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same
US9422290B2 (en) 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
JP2016525531A (ja) * 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 急性骨髄性白血病及び骨髄異形成症候群の処置のためのアザシチジンと組み合わせたボラセルチブ

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015531365A (ja) * 2012-09-28 2015-11-02 オンコエシックス エスエー チエノトリアゾロジアゼピン化合物を含む医薬製剤
JP2015537021A (ja) * 2012-11-16 2015-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング トリアゾロピラジン
JP2016530259A (ja) * 2013-08-14 2016-09-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジノン
JP2016540742A (ja) * 2013-11-07 2016-12-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｒｄ４阻害薬としてのトリアゾロピラジン誘導体
JP2017517565A (ja) * 2014-05-09 2017-06-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンゾイミダゾール誘導体
JP2017529358A (ja) * 2014-09-19 2017-10-05 ジェネンテック， インコーポレイテッド がんの処置のためのｃｂｐ／ｅｐ３００阻害剤およびｂｅｔ阻害剤の使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALBRECHT, B. K. ET AL: "Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, JPN6022053857, 2016, pages 1330 - 1339, ISSN: 0005102809 *
KING, B. ET AL: "The Ubiquitin Ligase FBXW7 Modulates Leukemia-Initiating Cell Activity by Regulating MYC Stability", CELL, vol. 153, JPN6022053858, 2013, pages 1552 - 1566, ISSN: 0005102810 *
MIRGUET, O. ET AL: "Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibit", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, JPN6022053856, 2013, pages 7501 - 7515, ISSN: 0005102808 *
NIETO-JIMENEZ, C. ET AL: "Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kin", ONCOTARGET, vol. 8, no. 12, JPN6022053855, 2017, pages 19478 - 19490, ISSN: 0005102807 *

Also Published As

Publication number Publication date
EP3743067A1 (en) 2020-12-02
CN111629725A (zh) 2020-09-04
US20210038602A1 (en) 2021-02-11
WO2019145410A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
US20260035393A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2020210312B2 (en) Certain chemical entities, compositions, and methods
JP6523490B2 (ja) ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
CN103282364B (zh) 咪唑并[4,5-c]喹啉-2-酮化合物及其作为pi3激酶/mtor双重抑制剂的用途
CN106188138B (zh) 一种二氨基嘧啶化合物及包含该化合物的组合物
EP2785325B1 (en) Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
EP3502103B1 (en) Crystal form, salt type of substituted 2-hydro-pyrazole derivative and preparation method therefor
US11459334B2 (en) Substituted pyrrolo[2,1-f][1,2,4]triazines as KIT and/or PDGFR-α inhibitors
AU2017302019A1 (en) Macrocycle kinase inhibitors
CA3099018A1 (en) Rip1 inhibitory compounds and methods for making and using the same
AU2014254050B2 (en) Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
KR20190016976A (ko) Pi3k 베타 저해제로서의 아자벤즈이미다졸 유도체
CN107995911A (zh) 苯并氧氮杂*噁唑烷酮化合物及其使用方法
WO2016150800A1 (en) Usp7 inhibitor compounds and methods of use
JP2021511352A (ja) 急性骨髄性白血病の併用処置
US10173995B2 (en) Pyridine compounds used as PI3 kinase inhibitors
CN115448874B (zh) 固体形式的周期蛋白依赖性激酶9抑制剂及其用途
KR20170095243A (ko) Pi3kbeta 저해제로서의 헤테로사이클릴 연결된 이미다조피리다진 유도체
BR112019020309A2 (pt) derivados de quinoxalina e piridopirazina como inibidores de pi3k-beta
US20230090742A1 (en) Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors
WO2026090300A1 (en) Compounds and uses thereof
CN121045188A (zh) 1,2-二氢吡咯并[1,2-a]吡嗪-3(4H)-酮衍生物及其用途
CN120418243A (zh) 一种Malt1抑制剂的磷酸酯前药
EA049465B1 (ru) Комбинированная терапия для лечения рака
HK40015557A (en) Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230710